Key figures as of December 31, 2017

 

Cash, cash equivalents and financial assets*

€153.8m

* Including current and non-current financial assets

Financial debt

€5.6m


Staff

>180 employees, 3/4 of whom are dedicated to R&D


Portfolio

  • 4 programs in clinical stage including one licensed to Bristol-Myers Squibb and one partnered with AstraZeneca
  • 1 portfolio of proprietary preclinical programs

See FY 2017 financial results

See HY 2017 financial results